Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at Oppenheimer; Inclisiran Moving Into Novartis' Hands
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $134.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
